BriaCell Therapeutics (NASDAQ:BCTX) Posts Quarterly Earnings Results, Beats Estimates By $0.45 EPS

BriaCell Therapeutics (NASDAQ:BCTX) issued its quarterly earnings data on Monday. The company reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.45, Yahoo Finance reports.

BriaCell Therapeutics Trading Down 0.8 %

BCTX stock traded down $0.01 during trading on Wednesday, reaching $0.83. The stock had a trading volume of 108,653 shares, compared to its average volume of 1,634,754. The firm has a market cap of $15.09 million, a PE ratio of -0.65 and a beta of 1.34. The stock’s 50 day moving average is $0.80 and its two-hundred day moving average is $1.15. BriaCell Therapeutics has a 52 week low of $0.46 and a 52 week high of $5.97.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and set a $15.00 target price on shares of BriaCell Therapeutics in a research note on Thursday, October 3rd.

BriaCell Therapeutics Company Profile

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.